Trials / Completed
CompletedNCT02593786
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether nivolumab is safe and effective in the treatment of advanced or recurrent solid tumors in Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab |
Timeline
- Start date
- 2016-01-07
- Primary completion
- 2021-09-27
- Completion
- 2021-09-27
- First posted
- 2015-11-02
- Last updated
- 2022-10-24
- Results posted
- 2022-10-24
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02593786. Inclusion in this directory is not an endorsement.